OVARIAN CANCER: MAKING ITS OWN RULES—AGAIN

Por Kohn, Elise C., Hurteau, Jean
Publicado em 2012

Confronting the Care Delivery Challenges Arising from Precision Medicine

Por Kohn, Elise C., Ivy, S. Percy
Publicado no Front Oncol (2016)

Extracellular Lipid-Mediated Signaling in Tumor-Cell Activation and Pseudopod Protrusion

Por Hodgson, Louis, Kohn, Elise C., Dong, Cheng
Publicado em 2000

Linking molecular therapeutics to molecular diagnostics: Inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo

Por Mills, Gordon B., Lu, Yiling, Kohn, Elise C.
Publicado em 2001

STAMP alters the growth of transformed and ovarian cancer cells

Por He, Yuanzheng, Blackford, John A, Kohn, Elise C, Simons, S Stoney
Publicado em 2010

Proteomics and Ovarian Cancer: Integrating Proteomics Information Into Clinical Care

Por Hays, John L., Kim, Geoffrey, Giuroiu, Iulia, Kohn, Elise C.
Publicado em 2010

Ovarian cancer treatment: The end of empiricism?

Por Lheureux, Stephanie, Karakasis, Katherine, Kohn, Elise C., Oza, Amit M.
Publicado no Cancer (2015)

Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP

Por Yokoyama, Takuhei, Kohn, Elise C., Brill, Ethan, Lee, Jung-Min
Publicado no Int J Oncol (2017)

Proteomics and biomarkers in clinical trials for drug development

Por Lee, Jung-min, Han, Jasmine J., Altwerger, Gary, Kohn, Elise C.
Publicado em 2011

Proteomics as a Tool for Biomarker Discovery

Por Kohn, Elise C., Azad, Nilofer, Annunziata, Christina, Dhamoon, Amit S., Whiteley, Gordon
Publicado em 2007

The MAPK pathway across different malignancies: A new perspective

Por Burotto, Mauricio, Chiou, Victoria L., Lee, Jung-Min, Kohn, Elise C.
Publicado no Cancer (2014)

OVEREXPRESSION OF PROTEASE INHIBITOR-DEAD SECRETORY LEUKOCYTE PROTEASE INHIBITOR CAUSES MORE AGGRESSIVE OVARIAN CANCER IN VITRO AND IN VIVO

Por Devoogdt, Nick, Rasool, Nabila, Hoskins, Ebony, Simpkins, Fiona, Tchabo, Nana, Kohn, Elise C.
Publicado em 2009

PROGRANULIN IS A POTENTIAL PROGNOSTIC BIOMARKER IN ADVANCED EPITHELIAL OVARIAN CANCERS

Por Han, Jasmine J., Yu, Minshu, Houston, Nicole, Steinberg, Seth M., Kohn, Elise C.
Publicado em 2010

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors

Por O’Sullivan, Ciara C., Moon, Dominic H., Kohn, Elise C., Lee, Jung-Min
Publicado em 2014

The Anti-Apoptotic Activity of BAG3 Is Restricted by Caspases and the Proteasome

Por Virador, Victoria M., Davidson, Ben, Czechowicz, Josephine, Mai, Alisha, Kassis, Jareer, Kohn, Elise C.
Publicado em 2009

Secretory Leukocyte Protease Inhibitor, SLPI, Antagonizes Paclitaxel in Ovarian Cancer Cells

Por Rasool, Nabila, LaRochelle, William, Zhong, Haihong, Ara, Gulshan, Cohen, Joshua, Kohn, Elise C.
Publicado em 2010

Targeted optical fluorescence imaging of human ovarian adenocarcinoma cells using a galactosyl serum albumin-conjugated fluorophore

Por Gunn, Andrew J., Hama, Yukihiro, Koyama, Yoshinori, Kohn, Elise C., Choyke, Peter L., Kobayashi, Hisataka
Publicado em 2007

Activation of NF-κB signaling by IKKβ increases aggressiveness of ovarian cancer

Por Hernandez, Lídia, Hsu, Sarah, Davidson, Ben, Birrer, Michael J., Kohn, Elise C., Annunziata, Christina M.
Publicado em 2010

Development of a multiparameter flow cytometric assay as a potential biomarker for homologous recombination deficiency in women with high-grade serous ovarian cancer

Por Lee, Jung-Min, Gordon, Nicolas, Trepel, Jane B, Lee, Min-Jung, Yu, Minshu, Kohn, Elise C
Publicado no J Transl Med (2015)

L-asparaginase inhibits invasive and angiogenic activity and induces autophagy in ovarian cancer

Por Yu, Minshu, Henning, Ryan, Walker, Amanda, Kim, Geoffrey, Perroy, Alyssa, Alessandro, Riccardo, Virador, Victoria, Kohn, Elise C
Publicado em 2012